Member Log-in

I forgot my password

Not a Member? Register

PATH Brief: Economic Implications of Switching Rotavirus Vaccine Products in Palestine’s Immunization Program

The Palestinian Ministry of Health (MOH) introduced the rotavirus vaccine ROTARIX® in its routine immunization program in 2016. Two years later, the MOH decided to switch to ROTAVAC®, a rotavirus vaccine made in India. Given the lower price of ROTAVAC, such a move might seem like a clear choice. In reality, the overall cost of vaccination programs is influenced by a variety of vaccine characteristics, such as the packaging volume and number of doses required. When comparing the health and economic value of different vaccine products, assessing multiple criteria beyond just price allows countries to account for the economic implications of all vaccine characteristics.

This switch therefore provided a unique opportunity to compare the overall costs, impact, and cost-effectiveness of both rotavirus vaccines in a public-sector setting. The resulting analysis, conducted by PATH and partners, found that both vaccines have a high probability of being cost-effective compared to no vaccination in Palestine. But when compared to ROTARIX, ROTAVAC was cost-saving. Find out more in this brief, available in English, French, Russian, and Arabic.

You May Also Like

PATH’s Vaccine Cost Calculators

PATH’s Vaccine Cost Calculators provide an easy way to assess and compare costs of certain vaccination programs over a period of 10 years with each vaccine product available in the global market. These Excel-based tools are available in multiple languages for rotavirus vaccines, pneumococcal conjugate vaccines, and human papillomavirus vaccines (coming soon!). The tools allow country-level policymakers … Continued

Assessing the Incremental Costs and Savings of Introducing Electronic Immunization Registries and Stock Management Systems: Evidence from the Better Immunization Data Initiative in Tanzania and Zambia

Introduction: poor data quality and use have been identified as key challenges that negatively impact immunization programs in low- and middle-income countries (LMICs). In addition, many LMICs have a shortage of health personnel, and staff available have demanding workloads across several health programs. In order to address these challenges, the Better Immunization Data (BID) Initiative … Continued

Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30

ABSTRACT Estimating the value of global investment in immunization programs is critical to helping decision makers plan and mobilize immunization programs and allocate resources required to realize their full benefits. We estimated economic benefits using cost-of-illness and value-of-a-statistical-life approaches and combined this estimation with immunization program costs to derive the return on investment from immunization … Continued

Choose a Language